Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Mabpharm Limited (2181) Stock Price & Analysis

0 Followers

2181 Stock Chart & Stats

HK$0.44-HK$0.04(-8.33%)
At close: 4:00 PM GMT+8
HK$0.4HK$0.45HK$0.5Aug 17Aug 31Sep 14Sep 30Oct 9Oct 26Nov 10
Day’s Range
HKD 0.43 - HKD 0.44
52-Week Range
HKD 0.31 - HKD 0.81
Previous Close
HKD 0.48
Volume
N/A
Average Volume (3M)
41.13K
Market Cap
HKD 1.81B
Enterprise Value
HKD 2.00B
Total Cash (Recent Filing)
HKD 93.31M
Total Debt (Recent Filing)
HKD 307.88M
Price to Earnings (P/E)
18.3
Beta
0.82
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Profitability Turnaround

The sharp 2025 revenue increase and return to positive earnings indicate improved commercial traction after several loss-making years. If growth persists, the larger revenue base can support operating leverage, strengthen reinvestment capacity, and improve the company’s ability to build sustainable earnings.

Strong Gross Margins

High gross margins indicate attractive product economics and provide a substantial contribution pool before operating expenses. This gives the company a foundation to scale profitably, invest in growth, and absorb some cost pressure, although conversion into operating profit remains important.

Positive Operating Cash Flow

Positive operating cash flow in 2025 shows that the business generated cash from its operations during the profitability turnaround. This supports day-to-day funding and provides an internal source for investment, even though significant outflows still prevented positive free cash flow.

Bears Say

Elevated Leverage

Elevated leverage increases financial risk because debt remains large relative to the equity base. It can reduce flexibility to fund growth, make the company more sensitive to weaker earnings or cash flow, and amplify the consequences of any operating setback.

Negative Free Cash Flow

Negative free cash flow means reported earnings were not converted into discretionary cash during 2025. This limits internally funded expansion and debt reduction, while the stated history of volatile cash generation suggests that cash support for earnings may remain inconsistent.

Thin Operating Profitability

A very low EBIT margin shows that most gross profit is absorbed by operating expenses, leaving limited protection if growth slows or costs increase. The company also recorded deeply negative margins from 2021 through 2024, underscoring the fragility of the recent improvement.

Mabpharm Limited News

2181 FAQ

What was Mabpharm Limited’s price range in the past 12 months?
Mabpharm Limited lowest stock price was HK$0.31 and its highest was HK$0.81 in the past 12 months.
What is Mabpharm Limited’s market cap?
Mabpharm Limited’s market cap is HK$1.81B.
When is Mabpharm Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mabpharm Limited’s earnings last quarter?
Mabpharm Limited released its earnings results on Aug 28, 2026. The company reported HK$0.009 earnings per share for the quarter.
Is Mabpharm Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Mabpharm Limited pay dividends?
Mabpharm Limited does not currently pay dividends.
What is Mabpharm Limited’s EPS estimate?
Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabpharm Limited have?
Mabpharm Limited has 4,124,080,000 shares outstanding.
What happened to Mabpharm Limited’s price movement after its last earnings report?
Mabpharm Limited reported an EPS of HK$0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mabpharm Limited?
Currently, no hedge funds are holding shares in HK:2181
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology